Phase II Study of Imatinib in Advanced Chordoma
- 20 March 2012
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (9), 914-920
- https://doi.org/10.1200/jco.2011.35.3656
Abstract
Purpose To explore the antitumor activity of imatinib in patients with advanced platelet-derived growth factor β (PDGFB)/PDGF receptor β (PDGFRB)–positive chordomas. Patients and Methods In a collaborative Italian-Swiss, prospective, phase II clinical study conducted from November 2004 through April 2006, 56 patients with advanced PDGFB and/or PDGFRB chordoma received 800 mg/d of imatinib until progression. The primary end point was the overall tumor response rate (ORR), defined by RECIST. Secondary, exploratory end points included tissue response (ie, changes in tumor density or signal intensity/contrast enhancement, and/or [18F]-fluorodeoxyglucose positron emission tomography [PET] uptake), overall survival, progression-free survival (PFS), and pain score. Results Among 50 patients evaluable by RECIST, the best response was one partial response (PR) obtained at 6 months (ORR, 2%). There were 35 patients with stable disease (SD, 70%) and a 64% clinical benefit rate (ie, RECIST complete response + PR + SD ≥ 6 months). A minor dimensional response (< 20%) was detected in nine patients. A maximum standard uptake value decrease ≥ 25% was observed in 10 (39%) of 26 patients evaluable for PET response at 3 months. Changes in the Brief Pain Inventory score were consistent with the response assessment. Median PFS (intention-to-treat population, 56 patients) was 9 months. No unexpected toxicities were observed. Conclusion This is the largest phase II study in chordoma to date. It confirms anecdotal evidence that imatinib has antitumor activity in this orphan disease, and therefore, it is worth further investigation.Keywords
This publication has 43 references indexed in Scilit:
- Chordoma of the Mobile Spine and Sacrum: A Retrospective Analysis of a Series of Patients Surgically Treated at Two Referral CentersAnnals of Surgical Oncology, 2009
- Clivus metastases: Report of seven patients and literature reviewActa Neurochirurgica, 2009
- Chordomas of the skull base: surgical management and outcomeJournal of Neurosurgery, 2007
- Patient Outcome at Long-term Follow-up after Aggressive Microsurgical Resection of Cranial Base ChordomasNeurosurgery, 2006
- ChordomasPublished by Wiley ,2006
- Chordoma of the Mobile Spine: Fifty Years of ExperienceSpine, 2006
- Sacral Chordoma: 40-Year Experience at a Major Cancer CenterNeurosurgery, 1999
- Chordoma of the mobile spine. A clinicopathologic analysis of 40 patientsCancer, 1993
- Chordoma: A Clinicopathologic Study of MetastasisAmerican Journal of Clinical Pathology, 1979
- Chordoma.Thirty-five-year study at memorial hospitalCancer, 1967